Shares Magazine
2.40p-0.05 (-2.04%)22 Nov 2024, 16:27
Jump to:
Genedrive PLC Fundamentals
| Company Name | Genedrive PLC | Last Updated | 2024-11-22 |
|---|---|---|---|
| Industry | Diagnostics & Research | Sector | Healthcare |
| Shares in Issue | 543.141 m | Market Cap | £13.04 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.04 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.0375 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | 2.2835 | Cash Equity Ratio | 0.8141 |
| Quick Ratio | 0.7450 | Current Ratio | 1.63 |
| Price To Book Value | 8.6580 | ROCE | 0 |
Genedrive PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Genedrive PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | £392,000.00 | £206,000.00 | £301,000.00 |
| Intangible Assets | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £392,000.00 | £206,000.00 | £348,000.00 |
| Stocks | £525,000.00 | £748,000.00 | £556,000.00 |
| Debtors | £50,000.00 | £47,000.00 | £93,000.00 |
| Cash & Equivalents | £2.60 m | £4.59 m | £2.57 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £4.51 m | £6.62 m | £4.88 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £2.45 m | £1.01 m | £1.28 m |
| Creditors after 1 year | £19,000.00 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £2.47 m | £1.01 m | £1.28 m |
| Net assets | £2.04 m | £5.61 m | £3.59 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £1.49 m | £1.39 m | £950,000.00 |
| Share Premium | £53.34 m | £52.43 m | £46.05 m |
| Profit / Loss | -£5.98 m | -£5.63 m | -£1.85 m |
| Other Equity | £2.04 m | £5.61 m | £3.59 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £2.04 m | £5.61 m | £3.59 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | £0.01 | 0 | 0 |
| Debt-to-Equity | £0.01 | 0 | 0 |
| Assets / Equity | 2.2835 | 2.2835 | 2.2835 |
| Cash / Equity | 0.8141 | 0.8141 | 0.8141 |
| EPS | -£0.04 | -£0.04 | -£0.05 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -£3.81 m | -£4.59 m | -£5.15 m |
| Cashflow before financing | -£1.98 m | £1.98 m | -£5.61 m |
| Increase in Cash | -£1.99 m | £2.01 m | -£5.61 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | £55,000.00 | £49,000.00 | £687,000.00 |
| Cost of sales | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Profit | 0 | 0 | 0 |
| Pre-Tax profit | -£5.98 m | -£5.63 m | -£1.85 m |
Genedrive PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Genedrive PLC is a holding company engaged in the molecular diagnostics business. It operates in one operating segment named Diagnostics which is engaged in the Genedrive Point of need molecular diagnostics platform for the diagnosis of infectious diseases and use in patient stratification (genotyping), pathogen detection, and other indications. Geographically the majority of the revenue is derived from the United Kingdom. |
| Latest Interim Date | 28 Mar 2024 |
| Latest Fiscal Year End Date | 29 Nov 2024 |
Genedrive PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2018-04-09 | Ms. Catherine Booth | Executive Director,Managing Director - Contract Research Ser |
| 2017-11-06 | Mr. Hugh John Joseph Rylands | Executive Director,Finance Director and Company Secretary |
| 2011-11-10 | Mr. Gerard Brady | Executive Director,Research Director |
| 2024-08-15 | Dr. Ian David Gilham | Non-Executive Director,Chairman |
| 2020-11-27 | Dr. Robert Dwyer Nolan | Non-Executive Director |
| 2015-04-28 | Mr. David Eric Evans | Non-Executive Director,Chairman |
| 2016-11-11 | Mr. Matthew Heaton Walls | Executive Director |
| 2013-11-26 | Mr. Jeffrey Gould Moore | Executive Director,Managing Director - Novel Therapies |
| 2012-11-22 | Professor Christopher Stanislaus Potten | Executive Director,Chief Scientific Adviser |
| 2020-11-27 | Dr. Roger Lloyd | Non-Executive Director |
| 2023-12-06 | Mr. Chris Henry Francis Yates | Non-Executive Director |
| 2017-11-08 | Dr. Allan Brown | Executive Director,Chief Operating Officer, Diagnostics |
| 2023-09-11 | Mr. David Budd | Executive Director,Chief Executive Officer |
| 2022-04-07 | Mr. Matthew John Fowler | Executive Director,Chief Financial Officer and Company Secretary |
| 2024-05-15 | Mr. Thomas Lindsay | Non-Executive Director |
| 2024-02-06 | Mr. Russell John Shaw | Executive Director,Chief Financial Officer and Company Secretary |
| 2024-08-06 | Mr. James Bernard Cheek | Executive Director,Chief Executive Officer |
| 2024-02-06 | Dr. Gino Miele | Executive Director,Chief Executive Officer |
Genedrive PLC Contact Details
| Company Name | Genedrive PLC |
|---|---|
| Address | 48 Grafton Street, The Incubator Building, Manchester, M13 9XX |
| Telephone | +44 1619890245 |
| Website | http://www.genedriveplc.com |
Genedrive PLC Advisors
| Solicitor | Covington & Burling LLP |
|---|---|
| Phone | +44 2070672000 |
| Fax | +44 2070672222 |
| Auditor | PricewaterhouseCoopers |
|---|
| Financial PR Adviser | Consilium Strategic Communications |
|---|---|
| Phone | +44 2037095700 |
| Stockbroker | Peel Hunt LLP |
|---|---|
| Phone | +44 2074188900 |
| Bank | Natwest Bank Plc |
|---|
| Registrar | Neville Registrars Ltd |
|---|---|
| Phone | +44 1215851131 |
| Fax | +44 1215851132 |
| Nominated Adviser | Peel Hunt LLP |
|---|---|
| Phone | +44 2074188900 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
